Translation of "Tumor recurrence" in German

However, preoperative irradiation seems to be mandatory in order to minimize the risk of tumor recurrence.

The goal of aftercare is to alleviate medical problems which may develop as part of the received medical treatment, and to recognise the emergence of new tumor growth (recurrence) and/or detect the development of metastases as early as possible and initiate treatment.

This is of particular interest in patients with surgical resection of the primary tumor or a tumor recurrence, and leads to an increased risk of the occurrence of intraabdominal tumor cells.

Histopathologic findings of lacrimal sac biopsy were correlated with preoperative symptoms and signs, medical history, intraoperative findings, further treatment modalities and clinical follow-up (including survival, recurrence, tumor clearance and surgical success).

The 59 patients evaluated to determine the clinical efficacy of treatment with Nano-Cancer® therapy with accompanying radiotherapy attained a median survival time following diagnosis of the first tumor recurrence of 13.4 months* (99% confidence interval: 9.7-17.1 months).

Available inhibitors of Hedgehog signaling all target the pathway upstream of the transcription factor GLI, whereas 4SC-208 inhibits several kinases associated with GLI and is thus potentially able to avoid the tumor recurrence and relapse observed in response to currently available inhibitors.

Available inhibitors of Hedgehog signaling target the pathway upstream of the transcription factor GLI, whereas 4SC-208 inhibits at the level of GLI and is thus potentially able to avoid the tumor recurrence and relapse observed in response to currently available inhibitors.

It is often used in the removal of both primary tumors and recurrent, especially those located on the skin of the face.

The solution found according to the invention of employing the trifunctional bispecific and/or trispecific antibodies described here intraoperatively after tumor resection, preferably directly locally in the abdominal cavity, forms the decisive novel approach to a successful perioperative tumor therapy, in particular to the prophylaxis of tumor recurrences, in particular peritoneal carcinomatoses, by destruction of freely disseminated tumor cells in the abdominal cavity.

However, it is novel and surprising that during a surgical intervention, after the tumor resection in the abdominal cavity these antibodies are also successfully applied preferably directly at the site of the operation, i.e. locally into the abdominal cavity, in order to destroy there intraperitoneally disseminated tumor cells which, for example, were detached from the tumor body by the intervention or were already present there due to dissemination from the tumor, and thus to prevent them from spreading in the body and the formation of tumor recurrences.

According to the invention, the trifunctional antibodies are thus employed for the prophylaxis and therapy of tumor recurrences which are caused in particular due to the surgical intervention and the tumor cells which have thereby disseminated, and in particular during the operation phase, as long as the abdominal cavity is open and has not yet been closed.

The term “disseminated cancer cell” is defined in particular in relation to solid tumors, that is to say in particular primary tumors, metastases and recurrences.

The requirements of tumor prevention or aftercare programs are to diagnose primary tumors or recurrences early, or metastases even before they become clinically manifest.

It is expected that individual s who participate in th is 10- subject study will be recruited principally from the pool of current bladder cancer patients at the Medical Center who meet specific criteria: men and women 18 years or older of any racial or ethnic origin, who are scheduled for a transurethral resection of bladder tumor (TURBT) in the operating room resulting from either a new diagnosis of a potentially malignant bladder mass, or a recurrent tumor .